Camp4 Therapeutics (CAMP) Common Equity (2023 - 2026)

Camp4 Therapeutics has reported Common Equity for 4 years, with the latest figure at $30.9 million in Q1 2026.

• Quarterly Common Equity fell 40.08% year-over-year to $30.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 40.08% YoY) and the FY2025 annual result came in at $47.7 million, down 24.45% from the prior year.
• Common Equity eased to $30.9 million in Q1 2026 per CAMP's latest filing, from $47.7 million in the prior quarter.
• Over five years, Common Equity peaked at $63.1 million in Q4 2024 and troughed at -$159.0 million in Q3 2024.
• A 4-year average of -$35.0 million and a median of $30.9 million in 2026 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 151.03% in 2024, down 42.51% in 2024.
• Over 4 years, Common Equity stood at -$123.7 million in 2023, then surged by 151.03% to $63.1 million in 2024, then fell by 24.45% to $47.7 million in 2025, then slumped by 35.22% to $30.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $30.9 million, $47.7 million, and $58.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.